Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours
Identifieur interne : 000172 ( Main/Exploration ); précédent : 000171; suivant : 000173Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours
Auteurs : RBID : ISTEX:259_1994_Article_BF00173045.pdfEnglish descriptors
- KwdEn :
Abstract
Two recently developed radiopharmaceuticals, iodine-131 metaiodobenzylguanidine (MIBG) and indium-111 pentetreotide, are currently being used for the diagnosis and therapy of neural crest tumours by interaction with the characteristic features of these tumours, such as an active uptake-I mechanism at the cell membrane and the presence of vesicles or neurosecretory granules in the cytoplasm and of specific receptors at the cell membrane. This review focusses on the role of MIBG and somatostatin analogues in the management of neural crest tumours. A number of aspects of both tracers are compared and the cumulative results are reviewed. Other uses of these radiopharmaceuticals are mentioned. It is concluded that both 111In-pentetreotide and 123I/131-MIBG are sensitive indicators of neural crest tumours, and have a complementary role. Unlike MIBG, 111In-pentetreotide is not specific for neural crest tumours, as scintigraphy is also positive in many other tumours, granulomas and autoimmune diseases. 131I-MIBG is effective in the therapy of several neural crest tumours; the biodistribution of 111In-pentetreotide at present does not allow radionuclide therapy using a beta-emitting label. However, as an indicator of somatostatin receptors, 111In-pentetreotide scintigraphy may be a predictor of response to palliative treatment with unlabelled octreotide. Recommendations for the use of these procedures are given.
DOI: 10.1007/BF00173045
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title>Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours</title><author><name>C. A. Hoefnagel</name><affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, The Netherlands Cancer Institute, Plesmanlaan 121, NL-1066 CX, Amsterdam, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Nuclear Medicine, The Netherlands Cancer Institute, Plesmanlaan 121, NL-1066 CX, Amsterdam</wicri:regionArea><wicri:noRegion>Amsterdam</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="RBID">ISTEX:259_1994_Article_BF00173045.pdf</idno><date when="1994">1994</date><idno type="doi">10.1007/BF00173045</idno><idno type="wicri:Area/Main/Corpus">000D99</idno><idno type="wicri:Area/Main/Curation">000D99</idno><idno type="wicri:Area/Main/Exploration">000172</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Indium-111 pentetreotide</term><term>Iodine-131 metaiodobenzylguanidine</term><term>Neural crest tumours</term><term>Therapy</term><term>Tumour imaging</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="eng">Two recently developed radiopharmaceuticals, iodine-131 metaiodobenzylguanidine (MIBG) and indium-111 pentetreotide, are currently being used for the diagnosis and therapy of neural crest tumours by interaction with the characteristic features of these tumours, such as an active uptake-I mechanism at the cell membrane and the presence of vesicles or neurosecretory granules in the cytoplasm and of specific receptors at the cell membrane. This review focusses on the role of MIBG and somatostatin analogues in the management of neural crest tumours. A number of aspects of both tracers are compared and the cumulative results are reviewed. Other uses of these radiopharmaceuticals are mentioned. It is concluded that both 111In-pentetreotide and 123I/131-MIBG are sensitive indicators of neural crest tumours, and have a complementary role. Unlike MIBG, 111In-pentetreotide is not specific for neural crest tumours, as scintigraphy is also positive in many other tumours, granulomas and autoimmune diseases. 131I-MIBG is effective in the therapy of several neural crest tumours; the biodistribution of 111In-pentetreotide at present does not allow radionuclide therapy using a beta-emitting label. However, as an indicator of somatostatin receptors, 111In-pentetreotide scintigraphy may be a predictor of response to palliative treatment with unlabelled octreotide. Recommendations for the use of these procedures are given.</div></front></TEI><mods xsi:schemaLocation="http://www.loc.gov/mods/v3 file:///applis/istex/home/loadistex/home/etc/xsd/mods.xsd" version="3.4" istexId="f1a55448842e3ec0d5f0e806396af006a475857e"><titleInfo lang="eng"><title>Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours</title></titleInfo><name type="personal"><namePart type="given">C. A.</namePart><namePart type="family">Hoefnagel</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, The Netherlands Cancer Institute, Plesmanlaan 121, NL-1066 CX, Amsterdam, The Netherlands</affiliation></name><typeOfResource>text</typeOfResource><genre>Review Article</genre><genre>Original Paper</genre><originInfo><publisher>Springer-Verlag, Berlin/Heidelberg</publisher><dateValid encoding="w3cdtf">2004-07-02</dateValid><copyrightDate encoding="w3cdtf">1994</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="eng">Two recently developed radiopharmaceuticals, iodine-131 metaiodobenzylguanidine (MIBG) and indium-111 pentetreotide, are currently being used for the diagnosis and therapy of neural crest tumours by interaction with the characteristic features of these tumours, such as an active uptake-I mechanism at the cell membrane and the presence of vesicles or neurosecretory granules in the cytoplasm and of specific receptors at the cell membrane. This review focusses on the role of MIBG and somatostatin analogues in the management of neural crest tumours. A number of aspects of both tracers are compared and the cumulative results are reviewed. Other uses of these radiopharmaceuticals are mentioned. It is concluded that both 111In-pentetreotide and 123I/131-MIBG are sensitive indicators of neural crest tumours, and have a complementary role. Unlike MIBG, 111In-pentetreotide is not specific for neural crest tumours, as scintigraphy is also positive in many other tumours, granulomas and autoimmune diseases. 131I-MIBG is effective in the therapy of several neural crest tumours; the biodistribution of 111In-pentetreotide at present does not allow radionuclide therapy using a beta-emitting label. However, as an indicator of somatostatin receptors, 111In-pentetreotide scintigraphy may be a predictor of response to palliative treatment with unlabelled octreotide. Recommendations for the use of these procedures are given.</abstract><subject lang="eng"><genre>Key words</genre><topic>Iodine-131 metaiodobenzylguanidine</topic><topic>Indium-111 pentetreotide</topic><topic>Neural crest tumours</topic><topic>Tumour imaging</topic><topic>Therapy</topic></subject><relatedItem type="series"><titleInfo type="abbreviated"><title>Eur J Nucl Med</title></titleInfo><titleInfo><title>European Journal of Nuclear Medicine</title><partNumber>Year: 1994</partNumber><partNumber>Volume: 21</partNumber><partNumber>Number: 6</partNumber></titleInfo><genre>Archive Journal</genre><originInfo><dateIssued encoding="w3cdtf">1994-06-01</dateIssued><copyrightDate encoding="w3cdtf">1994</copyrightDate></originInfo><subject usage="primary"><topic>Medicine & Public Health</topic><topic>Imaging / Radiology</topic><topic>Nuclear Medicine</topic></subject><identifier type="issn">0340-6997</identifier><identifier type="issn">Electronic: 1619-7089</identifier><identifier type="matrixNumber">259</identifier><identifier type="local">IssueArticleCount: 20</identifier><recordInfo><recordOrigin>Springer-Verlag, 1994</recordOrigin></recordInfo></relatedItem><identifier type="doi">10.1007/BF00173045</identifier><identifier type="matrixNumber">Art15</identifier><identifier type="local">BF00173045</identifier><accessCondition type="use and reproduction">MetadataGrant: OpenAccess</accessCondition><accessCondition type="use and reproduction">AbstractGrant: OpenAccess</accessCondition><accessCondition type="restriction on access">BodyPDFGrant: Restricted</accessCondition><accessCondition type="restriction on access">BodyHTMLGrant: Restricted</accessCondition><accessCondition type="restriction on access">BibliographyGrant: Restricted</accessCondition><accessCondition type="restriction on access">ESMGrant: Restricted</accessCondition><part><extent unit="pages"><start>561</start><end>581</end></extent></part><recordInfo><recordOrigin>Springer-Verlag, 1994</recordOrigin><recordIdentifier>259_1994_Article_BF00173045.pdf</recordIdentifier></recordInfo></mods></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000172 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000172 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:259_1994_Article_BF00173045.pdf
|texte= Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours
}}
| This area was generated with Dilib version V0.5.81. |  |